Cameron W. Brennan: Publications


Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP. Identification of DOK genes as lung tumor suppressors. Nat Genet., Feb. 2010. [Epub ahead of print]

Verhaak RGW, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Hidgson JGH, James D, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM and Hayes DN. The Cancer Genome Atlas Research Network. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell, Jan. 2010.

Cheng YW, Idrees K, Shattock R, Khan SA, Zeng Z, Brennan CW, Paty P, Barany F. Loss of imprinting and marked gene elevation are two forms of aberrant IGF2 expression in colorectal cancer. Int J Cancer (Epub ahead of print), Dec. 2009.

Brennan C*, Momota H*, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. *Co-first authors; Co-corresponding. PLoS One 4(11), Nov. 2009.

Chitale D, Gong Y, Taylor B, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Venkatraman ES, Zakowski M, Rusch V, Pao W, Gerald W and Ladanyi M. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28(31):2773-83, Aug 2009.

McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SMG, Nghiemphu P, Liau L, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers CL, Brennan C, Messaien L, Mellinghoff IK, Cichowski K. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell, 16(1):44-54, June 2009.

Veeriah S, Brennan C, Meng S, Singh B, Fagin J, Solit D, Paty P, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald W, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IM, Chan TA. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. PNAS 106(23):9435-40, Jun 2009.

Huse JT, Brennan C, Hambardzumyan D, Pena J, Rouhanifard SH, Sohn-Lee C, leSage C, Agami R, Tuschl T and Holland EC. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes and Development 23(11):1327-37, Jun 2009.

Peck KK, Bradbury M, Petrovich N, Hou BL, Ichill N, Brennan C, Tabar V, Holodny AI. Presurgical evaluation of language using functional magnetic resonance imaging in brain tumor patients with previous surgery. Neurosurgery 64(4):644-52, Apr 2009.

Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 6;4(3):226-35, Mar 2009.

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller D, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L and DePinho RA. Pten and p53 Converge on c-Myc to Control Differentiation, Self-renewal, and Transformation of Normal and Neoplastic Stem Cells in Glioblastoma. Cold Spring Harb Symp Quant Biol. 73:427-37, Jan 2009.

The Cancer Genome Atlas Research Network (multiple equal coauthors). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), Oct. 2008.

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller D, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L and DePinho RA. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature, 455(7216), Oct. 2008.

(Wiedemeyer R, Brennan C)*, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Furnari F, Cavenee WK, Chu GC, Stratton MR, Ligon KL, Futreal PA and Chin L. Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. Cancer Cell, 13(4), Apr. 2008. *Co-first authors.

Ruff IM, Brennan NMP, Peck KK, Hou BL, Tabar V, Brennan CW, Holodny AI. Assessment of the language laterality index in patients with brain tumor using functional MR imaging: effects of thresholding, task selection, and prior surgery. AJNR, 29(3), Mar 2008.

Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH and Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. PNAS, 104(52):20932-7, Dec. 2007.

Narayana A, Chang J, Yenice K, Chan K, Lymberis S, Brennan C, Gutin P. Hypofractionated Stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases. Stereotactic and Functional Neurosurgery, 85(2-3):82-87; Dec. 2007.

Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK .Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes and Devel., 21(21):2683-710, Nov. 2007.

Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC, Protopopov A, Ivanova E, Brennan C, Montgomery K, Kucherlapati R, Bailey G, Redston M, Chin L, DePinho RA. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res., 67(22):10736-43. Nov. 2007.

Stommel J, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Brennan C, Chin L, and DePinho RA. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318(5848):287-90, Oct. 2007.

Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O’neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, Depinho RA. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 447(7147):966-71, Jun 21, 2007.

Maher E, Brennan C, Wen P, Durso L, Ligon K, Richardson A, Khatry D, Feng B, Sinha R, Louis DN, Quakenbush J, Black P, Chin L, and DePinho RA. Marked genomic differences characterize primary and secondary GBM subtypes and identify two distinct molecular and clinical secondary GBM entities. Cancer Research, 66(23):11502-13; Dec 1, 2006.

Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, Jiang X, Yu Y, Brosius A, Thomas M, Chin L, Brennan C, DePinho RA, Kohane I, Carroll RS, Black PM, Johnson MD. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Research, 66(22):10815-23; Nov 6, 2006.

Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, Flotte TJ, Duncan LM, Granter SR, Chin L. Comparative Oncogenomics Identifies NEDD9 As a Melanoma Metastasis Gene. Cell, 127(7):1269-81; June 30, 2006.

Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, (Shaughnessy J, Brennan C, and DePinho RA)*. High-resolution Genomic Profiles Defines Distinct Clinico-Pathogenetic Subgroups of Multiple Myeloma Patients. Cancer Cell, 9(4):313-25; April, 2006. *co-corresponding authors.